US 11,754,566 B2
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Joseph Anderberg, Encinitas, CA (US); Jeff Gray, Solana Beach, CA (US); Paul McPherson, Encinitas, CA (US); and Kevin Nakamura, Cardiff By The Sea, CA (US)
Assigned to ASTUTE MEDICAL, INC., San Diego, CA (US)
Filed by ASTUTE MEDICAL, INC., San Diego, CA (US)
Filed on Oct. 30, 2020, as Appl. No. 17/85,566.
Application 14/327,513 is a division of application No. 13/125,360, granted, now 8,778,615, issued on Jul. 15, 2014, previously published as PCT/US2009/061561, filed on Oct. 21, 2009.
Application 17/085,566 is a continuation of application No. 14/327,513, filed on Jul. 9, 2014, granted, now 10,823,733.
Claims priority of provisional application 61/117,141, filed on Nov. 22, 2008.
Claims priority of provisional application 61/117,140, filed on Nov. 22, 2008.
Claims priority of provisional application 61/117,152, filed on Nov. 22, 2008.
Claims priority of provisional application 61/117,154, filed on Nov. 22, 2008.
Claims priority of provisional application 61/117,172, filed on Nov. 22, 2008.
Claims priority of provisional application 61/117,167, filed on Nov. 22, 2008.
Claims priority of provisional application 61/117,157, filed on Nov. 22, 2008.
Claims priority of provisional application 61/117,146, filed on Nov. 22, 2008.
Claims priority of provisional application 61/115,057, filed on Nov. 15, 2008.
Claims priority of provisional application 61/115,047, filed on Nov. 15, 2008.
Claims priority of provisional application 61/115,044, filed on Nov. 15, 2008.
Claims priority of provisional application 61/115,045, filed on Nov. 15, 2008.
Claims priority of provisional application 61/115,051, filed on Nov. 15, 2008.
Claims priority of provisional application 61/115,048, filed on Nov. 15, 2008.
Claims priority of provisional application 61/115,017, filed on Nov. 14, 2008.
Claims priority of provisional application 61/115,019, filed on Nov. 14, 2008.
Claims priority of provisional application 61/115,022, filed on Nov. 14, 2008.
Claims priority of provisional application 61/113,050, filed on Nov. 10, 2008.
Claims priority of provisional application 61/113,096, filed on Nov. 10, 2008.
Claims priority of provisional application 61/113,021, filed on Nov. 10, 2008.
Claims priority of provisional application 61/113,102, filed on Nov. 10, 2008.
Claims priority of provisional application 61/113,045, filed on Nov. 10, 2008.
Claims priority of provisional application 61/113,083, filed on Nov. 10, 2008.
Claims priority of provisional application 61/113,056, filed on Nov. 10, 2008.
Claims priority of provisional application 61/107,304, filed on Oct. 21, 2008.
Claims priority of provisional application 61/107,290, filed on Oct. 21, 2008.
Claims priority of provisional application 61/107,281, filed on Oct. 21, 2008.
Claims priority of provisional application 61/107,301, filed on Oct. 21, 2008.
Claims priority of provisional application 61/107,297, filed on Oct. 21, 2008.
Prior Publication US 2021/0055298 A1, Feb. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/573 (2006.01); G01N 33/68 (2006.01); G01N 33/50 (2006.01)
CPC G01N 33/573 (2013.01) [G01N 33/5088 (2013.01); G01N 33/5091 (2013.01); G01N 33/6893 (2013.01); G01N 2800/347 (2013.01); G01N 2800/50 (2013.01); G01N 2800/56 (2013.01); G01N 2800/60 (2013.01)] 19 Claims
 
1. A method for evaluating renal status in a subject and treating the subject based on the evaluation, the method comprising:
performing an assay configured to detect Metalloproteinase inhibitor 2 in a body fluid sample obtained from the subject to generate an assay result;
correlating the assay result to an increased risk of having acute kidney injury within 7 days of the time at which the sample is obtained from the subject when the assay result is above a predetermined threshold; and
treating the subject having the increased risk of having acute kidney injury within 7 days with a compatible treatment regimen, wherein the compatible treatment regimen comprises one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying procedures that are known to be damaging to the kidney, modifying diuretic administration, and monitoring kidney reperfusion.